Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.

Srivastava, Geetika; A Renfro, Lindsay; J Behrens, Robert; Lopatin, Margarita; Chao, Calvin; S Soori, Gamini; R Dakhil, Shaker; B Mowat, Rex; Philip Kuebler, J; Kim, George; Mazurczak, Miroslaw; Lee, Mark; R Alberts, Steven

doi:10.1634/theoncologist.2013-0401

Public

Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients.

Shared by NobleBlocks on May 1, 2014 • 12:00 AM UTC

Authors:

Geetika Srivastava

Lindsay A Renfro

Robert J Behrens

Abstract

The Oncotype DX colon cancer assay is a clinically validated predictor of recurrence risk in stage II colon cancer patients. This prospective study evaluated the impact of recurrence score (RS) results on physician recommendations regarding adjuvant chemotherapy in T3, mismatch repair-proficient (MM...

Subject

Adjuvant

Chemotherapy

Colon cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!